Novo Nordisk A/S
DEEURNovo Nordisk A/S (US:NONOF) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 3. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
- Novo Nordisk A/S — NOVO-B · CO DK Registrierungsnummer unbekannt
Über das Unternehmen
- Website
- novonordisk.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- BAGSVAERD DENMARK, Denmark
- CEO
- Maziar Mike Doustdar
- Mitarbeiter
- 66 700
- Ausstehende Aktien
- 3.34 Mrd.
- Streubesitz
- 3.17 Mrd.
- Marktkapitalisierung
- 150.93 Mrd. EUR
- Insider
- 5.27%
- Institutionelle Anleger
- 33.78%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- ZRPO
- ISIN
- DK0060534915
- LEI
- 549300DAQ1CVT6CXN342
- Ausschüttungsquote
- 50.5%
- FCF
- 59.0 Mrd. DKK
- Ausschüttung / FCF
- 88%
- Schulden
- 143 Mrd. DKK2.0 J. FCF
- Dividendenserie
- 24 J.
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 31.12.2025 (letzter Bericht des Unternehmens).
Beschreibung
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Dividenden
Novo Nordisk A/S (NONOF) zahlt zweimal jährlich Dividenden. Pro Jahr (12 Monate bis einschließlich der zuletzt angekündigten Zahlung): 11.7 DKK pro Aktie (Zahlungen: 2). Basierend auf der Zahlungshistorie wird der nächste Ex-Dividenden-Tag um den 15.02.2027 erwartet. Ununterbrochene Dividendengeschichte: 24 Jahre.
| Ex-tag | Auszahlung | Betrag | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-08-17 | 2026-08-18 | 3.7500 DKK | 1.2/3.9 % | halbjährlich | US:NONOF |
| 2026-03-30 | 2026-03-31 | 7.9500 DKK | 3.4/5.0 % | halbjährlich | US:NONOF |
| 2025-08-18 | 2025-08-19 | 3.7500 DKK | 1.1/3.4 % | halbjährlich | US:NONOF |
| 2025-03-31 | 2025-04-01 | 7.9000 DKK | 1.7/2.5 % | halbjährlich | US:NONOF |
| 2024-08-16 | 2024-08-19 | 3.5000 DKK | 1.4/3.8 % | halbjährlich | US:NONOF |
| 2024-03-22 | 2024-03-26 | 6.4000 DKK | 2.5/≈5.0 % | halbjährlich | US:NONOF |
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.38% | 46.88 Mio. | 2026-07-31 |
| EuroPacific Growth Fund-… | 1.07% | 36.2 Mio. | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.92% | 31.13 Mio. | 2026-06-30 |
| Capital World Growth & I… | 0.77% | 26.02 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.71% | 24.13 Mio. | 2026-08-31 |
| Income Fund of America | 0.52% | 17.78 Mio. | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 0.39% | 13.1 Mio. | 2026-06-30 |
| Fidelity Concord Street… | 0.37% | 12.52 Mio. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.34% | 11.48 Mio. | 2026-08-31 |
| Capital Income Builder | 0.3% | 10.32 Mio. | 2026-07-31 |
| Cygnus Capital Advisors,… | 0% | 78 800 | 2026-06-30 |
| Generali Investments Cee… | 0% | 27 399 | 2026-06-30 |
| Pacer Advisors, Inc. | 0% | 24 410 | 2026-06-30 |
| Atlas Capital Advisors I… | 0% | 5 218 | 2026-06-30 |
| Novo Holdings | — | — | — |
| Novo Nordisk Foundation | — | — | — |
